Compare CNDT & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNDT | DTIL |
|---|---|---|
| Founded | 2016 | 2006 |
| Country | United States | United States |
| Employees | 51000 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 234.2M | 197.9M |
| IPO Year | 2016 | 2019 |
| Metric | CNDT | DTIL |
|---|---|---|
| Price | $1.50 | $6.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $29.40 |
| AVG Volume (30 Days) | ★ 915.3K | 219.2K |
| Earning Date | 11-06-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,042,000,000.00 | $1,070,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.15 | $3.53 |
| 52 Week High | $2.63 | $9.62 |
| Indicator | CNDT | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 44.95 | 53.58 |
| Support Level | $1.31 | $6.62 |
| Resistance Level | $1.62 | $6.92 |
| Average True Range (ATR) | 0.08 | 0.38 |
| MACD | -0.01 | 0.09 |
| Stochastic Oscillator | 37.50 | 81.74 |
Conduent Inc acts as a provider of business process services with expertise in transaction-intensive processing, analytics, and automation. The company provides industry-focused service offerings in growth markets such as Healthcare and Transportation, as well as provides multi-industry services such as transaction processing, customer care, and payment services. It operates through three segments, namely Commercial Industries, which is the key revenue-driving segment, Government Services, and Transportation. The group operates its business in the United States, Europe, and Other areas, of which the majority of revenue is generated in the United States.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).